Literature DB >> 5245517

Administration of a mixture of fungal glucosidases to a patient with type II glycogenosis (Pompe's disease).

R M Lauer, T Mascarinas, A S Racela, A M Diehl, B I Brown.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1968        PMID: 5245517

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


× No keyword cloud information.
  7 in total

1.  Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease.

Authors:  A J McVie-Wylie; K L Lee; H Qiu; X Jin; H Do; R Gotschall; B L Thurberg; C Rogers; N Raben; M O'Callaghan; W Canfield; L Andrews; J M McPherson; R J Mattaliano
Journal:  Mol Genet Metab       Date:  2008-06-05       Impact factor: 4.797

2.  Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail.

Authors:  T Kikuchi; H W Yang; M Pennybacker; N Ichihara; M Mizutani; J L Van Hove; Y T Chen
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

3.  Heat-stable protein that stimulates acid alpha-glucosidase.

Authors:  N S Radin; A Shukla; G S Shukla; A Sano
Journal:  Biochem J       Date:  1989-12-15       Impact factor: 3.857

4.  Penetration of perfused rat liver by exogenous amyloglucosidase.

Authors:  D A Hems; R Ivings; B E Ryman
Journal:  Biochem J       Date:  1971-10       Impact factor: 3.857

Review 5.  The glycogen storage diseases.

Authors:  B E Ryman
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1974

6.  Recombinant caprine 3H-[N-acetylglucosamine-6-sulfatase] and human 3H-[N-acetylgalactosamine-4-sulfatase]: plasma clearance, tissue distribution, and cellular uptake in the rat.

Authors:  M Z Jones; L K Brumfield; B M King; J J Hopwood; S Byers
Journal:  J Mol Neurosci       Date:  1998-12       Impact factor: 3.444

Review 7.  Glyco-engineering strategies for the development of therapeutic enzymes with improved efficacy for the treatment of lysosomal storage diseases.

Authors:  Doo-Byoung Oh
Journal:  BMB Rep       Date:  2015-08       Impact factor: 4.778

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.